The real drug development delay? Bad communication.

Swiss pharmaceutical giant Novartis has agreed to buy London-based biotech Myricx Bio for up to $1.5bn (£1.1bn) as global ...

Brandon Capital will receive more than $300 million from the sale of Myricx, which is developing cancer-killing “biological ...

They have at least one thing in common: An exciting pipeline.

Parabilis Medicines, NewLimit, Enliven Therapeutics, and Kardigan bagged the biggest biotech funding rounds overall in June 2026.

Candel Therapeutics (CADL) shifts to late-stage oncology with CAN-2409 Phase III wins and BLA catalyst. Read here for a ...

Driven by looming patent cliffs, newly buoyant public markets, and Big Pharma's race to beef up their pipelines, dealmaking in 2026 is off to a strong start.

It has been a banner year for biotech buyouts, and these are two of the prime targets.

Biotech companies are spending billions to perfect chemical formulas, only to be tripped up by the one variable they forgot ...

As Greater Boston’s biotech industry sheds jobs, three unlikely regions are showing promise as up-and-coming hubs.

Biopharma dealmaking is driven by pressure to top up drug pipelines ahead of major patent expirations later this decade.

Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...